SCHEMBL25613085

SCHEMBL25613085

CC(C)(C)c1cc2cc[nH]c2nc1OC1CCNCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 6/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ PRKACA P17612 1/20 0.41
▸ PRKCD Q05655 1/20 0.41
▸ PRKG1 Q13976 1/20 0.41
▸ PKN1 Q16512 1/20 0.41
▸ PKN2 Q16513 1/20 0.41
▸ AAK1 Q2M2I8 1/20 0.41
▸ CDC42BPA Q5VT25 1/20 0.41
▸ Q6ZSR9 Q6ZSR9 1/20 0.41
▸ BMP2K Q9NSY1 1/20 0.41
▸ CDC42BPB Q9Y5S2 1/20 0.41
▸ PRKCZ Q05513 1/20 0.36
▸ JAK3 P52333 2/20 0.36
▸ IKBKB O14920 2/20 0.35
▸ HRH1 P35367 1/20 0.35
▸ MAP2K1 Q02750 1/20 0.33
▸ CHUK O15111 1/20 0.33
▸ FEN1 P39748 1/20 0.33
▸ SOS1 Q07889 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613074 0.93 PRKCZ (0.44) ROCK1ROCK2PRKACAPRKCDPRKG1
SCHEMBL25613062 0.92 JAK3 (0.39) ROCK1ROCK2PRKACAPRKCDPRKG1
SCHEMBL25613075 0.90 JAK3 (0.43) ROCK1JAK3FEN1
SCHEMBL25613086 0.90 JAK3 (0.46) ROCK1JAK3FEN1
SCHEMBL25613082 0.88 JAK3 (0.48) ROCK1JAK3FEN1
SCHEMBL25613079 0.87 FEN1 (0.34) ROCK1ROCK2PRKCDPRKCZJAK3
SCHEMBL25613083 0.85 LRRK2 (0.40) JAK3
SCHEMBL25613060 0.83 TTK (0.38) JAK3FEN1MAPK1
SCHEMBL25613078 0.82 PIK3CD (0.33) JAK3FEN1
SCHEMBL25613190 0.81 CTSD (0.32) JAK3FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 ROCK1 1179/4885ROCK2 179/4885PRKACA 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback